Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The company has appointed Dr. Ludger Dinkelborg, former CEO of Life Molecular Imaging, as Head of Research and Development effective August 1, 2025.
Through this strategic acquisition, Lantheus gains Neuraceq®, a globally approved F-18 PET imaging agent for detecting beta-amyloid plaques in Alzheimer's disease evaluation. The deal strengthens Lantheus's position in Alzheimer's diagnostics with enhanced commercial infrastructure, R&D capabilities, and international presence.
Lantheus Holdings (NASDAQ: LNTH) ha completato l'acquisizione di Life Molecular Imaging Ltd., una controllata di Life Healthcare Group Holdings Ltd. La società ha nominato Dr. Ludger Dinkelborg, ex CEO di Life Molecular Imaging, come Responsabile della Ricerca e Sviluppo a partire dal 1° agosto 2025.
Grazie a questa acquisizione strategica, Lantheus ottiene Neuraceq®, un agente di imaging PET F-18 approvato a livello globale per la rilevazione delle placche beta-amiloidi nella valutazione della malattia di Alzheimer. L'accordo rafforza la posizione di Lantheus nella diagnostica dell'Alzheimer, migliorando l'infrastruttura commerciale, le capacità di ricerca e sviluppo e la presenza internazionale.
Lantheus Holdings (NASDAQ: LNTH) ha completado la adquisición de Life Molecular Imaging Ltd., una subsidiaria de Life Healthcare Group Holdings Ltd. La compañía ha nombrado a Dr. Ludger Dinkelborg, ex CEO de Life Molecular Imaging, como Jefe de Investigación y Desarrollo a partir del 1 de agosto de 2025.
Con esta adquisición estratégica, Lantheus adquiere Neuraceq®, un agente de imagen PET F-18 aprobado a nivel mundial para detectar placas beta-amiloides en la evaluación de la enfermedad de Alzheimer. El acuerdo fortalece la posición de Lantheus en el diagnóstico del Alzheimer, con una infraestructura comercial mejorada, capacidades de I+D y presencia internacional ampliada.
Lantheus Holdings (NASDAQ: LNTH)는 Life Healthcare Group Holdings Ltd.의 자회사인 Life Molecular Imaging Ltd.의 인수를 완료했습니다. 회사는 Dr. Ludger Dinkelborg를 2025년 8월 1일부터 연구개발 책임자로 임명했습니다. 그는 전 Life Molecular Imaging의 CEO입니다.
이번 전략적 인수를 통해 Lantheus는 알츠하이머병 평가에서 베타-아밀로이드 플라크를 탐지하는 전 세계 승인된 F-18 PET 영상제제인 Neuraceq®를 확보했습니다. 이번 거래는 Lantheus의 알츠하이머 진단 분야에서의 입지를 강화하며, 상업 인프라, 연구개발 역량, 국제적 존재감을 향상시킵니다.
Lantheus Holdings (NASDAQ : LNTH) a finalisé l'acquisition de Life Molecular Imaging Ltd., une filiale de Life Healthcare Group Holdings Ltd. La société a nommé Dr Ludger Dinkelborg, ancien PDG de Life Molecular Imaging, au poste de Responsable de la Recherche et Développement à compter du 1er août 2025.
Grâce à cette acquisition stratégique, Lantheus obtient Neuraceq®, un agent d'imagerie PET F-18 approuvé mondialement pour détecter les plaques bêta-amyloïdes dans l’évaluation de la maladie d'Alzheimer. Cet accord renforce la position de Lantheus dans le diagnostic de la maladie d'Alzheimer, avec une infrastructure commerciale renforcée, des capacités de R&D accrues et une présence internationale élargie.
Lantheus Holdings (NASDAQ: LNTH) hat die Übernahme von Life Molecular Imaging Ltd., einer Tochtergesellschaft der Life Healthcare Group Holdings Ltd., abgeschlossen. Das Unternehmen hat Dr. Ludger Dinkelborg, den ehemaligen CEO von Life Molecular Imaging, zum Leiter der Forschung und Entwicklung mit Wirkung zum 1. August 2025 ernannt.
Durch diese strategische Übernahme erhält Lantheus Neuraceq®, einen weltweit zugelassenen F-18 PET-Bildgebungsagenten zur Erkennung von Beta-Amyloid-Plaques bei der Alzheimer-Diagnostik. Der Deal stärkt Lantheus’ Position im Bereich Alzheimer-Diagnostik durch verbesserte kommerzielle Infrastruktur, F&E-Fähigkeiten und internationale Präsenz.
- Acquisition of Neuraceq®, a globally approved Alzheimer's diagnostic imaging agent
- Strengthened leadership with appointment of experienced CEO Dr. Dinkelborg as Head of R&D
- Expanded international footprint and commercial infrastructure in Alzheimer's diagnostics
- Enhanced R&D capabilities and pipeline development potential
- Integration costs and challenges may impact short-term operations
- Increased operational complexity with expanded international presence
Insights
Lantheus strengthens Alzheimer's diagnostic capabilities through strategic Life Molecular acquisition, enhancing pipeline and global reach.
Lantheus' completed acquisition of Life Molecular Imaging represents a significant strategic expansion in the radiopharmaceutical space, particularly in Alzheimer's diagnostics. The addition of Neuraceq® (florbetaben F18 injection), an FDA-approved PET imaging agent for detecting beta-amyloid plaques, positions Lantheus to capitalize on the growing importance of early and accurate Alzheimer's diagnosis, especially as new disease-modifying treatments enter the market.
The appointment of Dr. Ludger Dinkelborg as Head of R&D brings valuable leadership to Lantheus at a critical time. His expertise in developing innovative radiopharmaceuticals will likely accelerate pipeline advancement and potentially lead to expanded indications for existing products. This leadership addition signals Lantheus' commitment to scientific innovation in precision diagnostics.
Beyond the product acquisition, this deal delivers three key strategic assets: 1) an established Alzheimer's disease radiodiagnostic commercial infrastructure, 2) enhanced R&D capabilities, and 3) an expanded international footprint. These components provide Lantheus with the operational foundation to scale its Alzheimer's diagnostic business globally while potentially reducing time-to-market for pipeline candidates.
This acquisition aligns with broader industry trends toward precision medicine in neurodegenerative diseases, where accurate diagnosis is becoming increasingly critical for treatment selection. As pharmaceutical companies continue developing targeted Alzheimer's therapies, the demand for companion diagnostics like Neuraceq is expected to grow substantially, potentially creating significant revenue opportunities for Lantheus.
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025.
“We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus,” said Brian Markison, CEO of Lantheus. “Ludger’s proven leadership, scientific expertise, and track record of advancing innovative radiopharmaceuticals will be instrumental as we expand and advance our innovative pipeline and pursue bold new opportunities to improve patient care.”
In his new role, Dr. Dinkelborg will lead and oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions and will report directly to the CEO.
“This is a pivotal moment for Lantheus, and I’m honored to help shape the next chapter,” said Dr. Dinkelborg. “With a strong pipeline and a passionate team, we have the opportunity to push the boundaries of innovation and bring meaningful advances to patients worldwide.”
Through the acquisition of Life Molecular, Lantheus gains Neuraceq® (florbetaben F18 injection), a globally1 approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease. The transaction also provides Lantheus a robust Alzheimer’s disease radiodiagnostic commercial infrastructure, advanced R&D capabilities, and an established international footprint.
RMB, a division of FirstRand Bank Limited, acted as financial advisor to Life Healthcare, with A&O Shearman LLP and Cliffe Dekker Hofmeyr Inc. as legal advisors. Morgan Stanley served as financial advisor to Lantheus, while Covington & Burling LLP, Ropes & Gray LLP, and Bowmans acted as legal advisors, and Ernst & Young LLP provided financial and tax advisory services.
About Neuraceq® (florbetaben F 18 injection)
Indication (approved by FDA on 23 June 2025)
Neuraceq® is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products
Important Safety Information
Risk for Image Interpretation and Other Errors
Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Neuraceq® image interpretation. The use of clinical information in the interpretation of Neuraceq® images has not been evaluated and may lead to an inaccurate assessment. Severe brain atrophy as well as motion artifacts that result in image distortion may limit the ability to distinguish gray and white matter on a Neuraceq® scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
Radiation Risk
Neuraceq® contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
Common Adverse Reactions
The overall safety profile of Neuraceq® is based on data from 1,090 administrations of Neuraceq® to 872 subjects. No serious adverse reactions related to Neuraceq® administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq® were injection site reactions consisting of pain (
Please see the Full Prescribing Information for Neuraceq® at www.Neuraceq.com.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.
1Neuraceq is approved in the United States, European Union, Canada, South Korea, China, and Japan
Contacts
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
FAQ
What did Lantheus (NASDAQ: LNTH) acquire in July 2025?
Who is the new Head of R&D at Lantheus?
What is Neuraceq® and what is it used for?
What strategic benefits does the Life Molecular acquisition bring to Lantheus?
Who were the advisors in the Lantheus-Life Molecular acquisition?
